Intrexon (NASDAQ:XON) and Redpoint Bio (OTCMKTS:RPBC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.
Insider & Institutional Ownership
75.9% of Intrexon shares are owned by institutional investors. 44.0% of Intrexon shares are owned by company insiders. Comparatively, 11.5% of Redpoint Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Intrexon and Redpoint Bio’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intrexon||$160.57 million||7.36||-$509.34 million||($1.37)||-5.36|
Redpoint Bio has lower revenue, but higher earnings than Intrexon.
This is a breakdown of recent ratings for Intrexon and Redpoint Bio, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intrexon presently has a consensus target price of $33.50, indicating a potential upside of 355.78%.
This table compares Intrexon and Redpoint Bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Intrexon beats Redpoint Bio on 4 of the 7 factors compared between the two stocks.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Redpoint Bio Company Profile
Redpoint Bio Corporation, a development stage biotechnology company, focuses on the development of healthier foods and new approaches for the treatment of diabetes and obesity by understanding the biology of taste and its relationship to metabolism, satiety, and diabetes. It enters into a license and commercialization agreement with International Flavors and Fragrances Inc. for the development, manufacture, use, and commercialization of RP44, which is a component of the stevia plant that works as a sweetness enhancer amplifying the existing sugary sweetness in a food or beverage. The company is based in Philadelphia, Pennsylvania.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.